According to ESC guidelines, what antithrombotic regimen is recommended after surgical mechanical valve replacement, surgical bioprosthetic valve replacement, and transcatheter aortic valve implantation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Antithrombotic Regimens After Valve Replacement According to ESC Guidelines

According to ESC 2017 guidelines, the recommended antithrombotic regimens are: for surgical mechanical valves—lifelong VKA therapy (INR 2.5 for aortic, INR 3.0 for mitral); for surgical bioprosthetic valves—VKA (INR 2.5) for the first 3 months after mitral/tricuspid replacement or aspirin 75-100 mg daily for the first 3 months after aortic replacement; and for TAVI—dual antiplatelet therapy (aspirin + clopidogrel) for 3-6 months followed by lifelong aspirin. 1

Surgical Mechanical Valve Replacement

Long-term Anticoagulation

  • All mechanical valves require lifelong VKA therapy 1
  • Aortic position: Target INR 2.5 (range 2.0-3.0) for bileaflet or current-generation tilting-disc valves without additional risk factors 1
  • Mitral position: Target INR 3.0 (range 2.5-3.5) regardless of valve type 1
  • Higher INR target (3.0) also required for aortic valves with additional risk factors (atrial fibrillation, prior thromboembolism, LV dysfunction, hypercoagulable state) or older-generation prostheses 1

Antiplatelet Therapy

  • ESC does NOT recommend routine aspirin addition to VKA therapy for mechanical valves 2
  • Consider adding aspirin only after thromboembolic event despite adequate INR (Class IIa) or with concomitant coronary artery disease (Class IIb) 2

Important caveat: This differs significantly from ACC/AHA guidelines, which recommend routine indefinite aspirin 75-100 mg daily in addition to VKA for all mechanical valves 3. The ESC takes a more conservative approach to minimize bleeding risk.

Surgical Bioprosthetic Valve Replacement

Initial Period (First 3 Months)

Mitral or Tricuspid Position:

  • VKA therapy targeting INR 2.5 should be considered for the first 3 months (Class IIa) 1

Aortic Position:

  • Low-dose aspirin (75-100 mg daily) should be considered for the first 3 months (Class IIa) 1
  • VKA therapy may be considered as an alternative (Class IIb) 1

Long-term Management

  • No indefinite anticoagulation or antiplatelet therapy is recommended for bioprosthetic valves unless there are other indications (atrial fibrillation, venous thromboembolism, hypercoagulable state, or severely impaired LV function with EF <35%) 1

Key difference from ACC/AHA: The ESC does not recommend indefinite aspirin for bioprosthetic valves, while ACC/AHA suggests lifelong aspirin 75-100 mg daily is reasonable 3, 2.

Transcatheter Aortic Valve Implantation (TAVI)

Patients WITHOUT Indication for Oral Anticoagulation

  • Dual antiplatelet therapy (aspirin 75-100 mg + clopidogrel 75 mg) should be considered for 3-6 months after TAVI (Class IIa) 1
  • Followed by lifelong single antiplatelet therapy (aspirin) 1
  • Single antiplatelet therapy may be considered from the outset in patients with high bleeding risk (Class IIb) 1

Patients WITH Indication for Oral Anticoagulation

  • Oral anticoagulation is recommended lifelong for standard indications (atrial fibrillation, etc.) 1
  • The specific regimen should follow standard anticoagulation guidelines for the underlying indication

Important Contraindication

  • NOACs (direct oral anticoagulants) are contraindicated in patients with mechanical prosthetic valves 1
  • Recent evidence suggests rivaroxaban 10 mg plus aspirin is contraindicated post-TAVI due to increased bleeding without benefit 3

Critical Clinical Considerations

Bridging Therapy

  • ESC recommends routine bridging with UFH or LMWH when interrupting VKA for procedures in mechanical valve patients (Class I) 2
  • This contrasts with ACC/AHA, which does NOT recommend bridging for low-risk patients with bileaflet aortic valves 2

Valve Repair

  • VKA should be considered for first 3 months after surgical mitral or tricuspid valve repair (Class IIa) 1

Combination with PCI

When patients with mechanical valves require PCI, the management becomes complex:

  • Triple therapy (VKA + aspirin + clopidogrel) should be considered for >1 month up to 6 months in high ischemic risk patients (Class IIa) 1
  • Dual therapy (VKA + clopidogrel) should be considered as alternative when bleeding risk outweighs ischemic risk (Class IIa) 1
  • INR should be kept in the lower part of target range with time in therapeutic range >65-70% 1

Common pitfall: Avoid prasugrel or ticagrelor as part of triple therapy—stick with clopidogrel 1.

References

Related Questions

In a 12‑month‑old male with normal growth and exam, which absent developmental milestone (e.g., pointing to a body part, responding to name, stacking two blocks, using a cup, or walking independently) would be most concerning and warrant further investigation?
In a 13‑day‑old infant presenting with fever and poor feeding, what interventions should emergency medical services (EMS) perform?
How should I manage a 10-month-old infant with a rectal temperature of 100.6 °F and two episodes of vomiting?
What are the differential diagnoses for aggressive behavior in a 10-year-old child?
In a 19-year-old college student with fever (103°F), severe headache, altered mental status, hypotension (90/55 mmHg), sluggish pupils, and leukocytosis with 20% band forms, what isolation precautions are indicated?
Will three vaginal doses of 400 µg misoprostol achieve the intended effect for a medical abortion after mifepristone?
How should Olaparib (Lynparza) be dosed or used in patients with impaired renal function, such as reduced creatinine clearance?
What are the indications, dosing regimen, contraindications, and adverse effects of Ocurest‑AH (phenylephrine and naphazoline) eye drops?
How is cross‑matching performed for packed red blood cell transfusion?
Is a direct bilirubin level of 0.4 mg/dL normal in an adult?
What is the role of the HIV‑1 proviral DNA test in diagnosing and managing HIV infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.